Document Detail


Beta-blocker therapy in heart failure in the elderly.
MedLine Citation:
PMID:  18023898     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic heart failure (CHF) is a common and disabling condition with morbidity and mortality that increase dramatically with advancing age. There is some evidence available about beta-blocker therapy in the elderly. The Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) and retrospective subgroup (elderly) analyses of landmark clinical trials in stable systolic heart failure have provided data supporting the use of beta-blocker as baseline therapy in heart failure in the elderly. However, beta-blocker is still less frequently used in elderly compared to younger patients. There are many reasons, one of which is that available data on elderly patients are not as convincing as those pertaining to their younger counterparts. There is uncertainty or disagreement about whether beta-blockers are equally beneficial and well tolerated in elderly heart failure patients as in younger ones. In other words, the level of evidence regarding beta-blocker therapy in the elderly is not regarded as high as that in younger patients. Indeed, the senior heart failure population, which in fact comprises the majority of all heart failure patients, is in general less well studied, both experimentally and clinically, than younger populations. Both clinical studies and experience indicate good tolerability in the use of beta-blocker in the elderly. Although beta-blockers are well tolerated by the elderly, target doses (based on previous clinical trials) may be difficult to achieve. The question is whether we should use the same target dose in the elderly as that in younger patients. Theoretically, the most effective dose is the highest dose tolerated, which may differ across different age groups. Is it time to abandon the "target dose" for the "highest dose tolerated"? The time has come to carry out active research to achieve better documentation of evidence based heart failure management in the elderly for the benefit of a large number of elderly patients with heart failure. We need clinical trial data that show definite improvement in outcomes as well as a clear-cut, favourable benefit-risk analysis involving beta-blockers in typical older heart failure patients irrespective of comorbidity and polypharmacy. Until the above is available, it may be wiser to adhere to beta-blocker therapy, which at present is better documented than other heart failure therapies in the elderly.
Authors:
Michael Fu
Related Documents :
447188 - Electrocardiographic and electrophysiologic studies of the univentricular hearts.
17355168 - Aldosterone antagonists: the most underutilized class of heart failure medications.
17105668 - Clinical characteristics of emergency department heart failure patients initially diagn...
19921298 - Anaemia is an independent predictor of death in patients hospitalized for acute heart f...
3756828 - Splenectomy in advanced chronic lymphocytic leukemia.
977778 - Severe selective igm deficiency.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-11-19
Journal Detail:
Title:  International journal of cardiology     Volume:  125     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-24     Completed Date:  2008-06-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  149-53     Citation Subset:  IM    
Affiliation:
Heart Failure Center Medicine, Sahlgrenska University Hospital/Sahlgrenska, 413 45 Göteborg, Sweden. Michael.fu@vgregion.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Aged
Aged, 80 and over
Heart Failure / drug therapy*,  pathology
Humans
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biventricular myocardial noncompaction presenting with complete atrioventricular block.
Next Document:  Debulking of chronic coronary total occlusions with rotational or directional atherectomy before ste...